PF-4708671 Licensed and Manufactured by Pfizer

Catalog No.S2163

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Price Stock Quantity  
USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

PF-4708671 Chemical Structure

PF-4708671 Chemical Structure
Molecular Weight: 390.41

Validation & Quality Control

2 customer reviews :

Quality Control & MSDS

Related Compound Libraries

PF-4708671 is available in the following compound libraries:

Product Information

  • Compare S6 Kinase Inhibitors
    Compare S6 Kinase Products
  • Research Area

Product Description

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.
Targets p70 S6K1 [1]
(Cell-free assay)
IC50 160 nM
In vitro PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
BHT-101MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTBwOEKwNlQh|ryPM37CXHNCVkeHUh?=
UACC-893NYfsTHZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTVwMUm4PFYh|ryPNX72UGQ5W0GQR1XS
A427MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPhTWM2OD13LkeyOVY4KM7:TR?=M{DMeXNCVkeHUh?=
OCUB-MM4nxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTZwNk[xNFIh|ryPMVTTRW5ITVJ?
SW684Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnmfGJ6UUN3ME23MlUzOjZ6IN88US=>NWj2cmY5W0GQR1XS
SK-LMS-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfEUllqUUN3ME25MlAyOzB{IN88US=>M12xZ3NCVkeHUh?=
CP50-MEL-BNX:zdFRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzWfG9KSzVyPUmuN|A1OTlizszNNGr4UZZUSU6JRWK=
NCI-H1651NX;O[|F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTFyLkCyO|Yh|ryPMYTTRW5ITVJ?
ABC-1MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\iZnFKSzVyPUGwMlExOzdizszNNWPKfoRPW0GQR1XS
OE19NWjyXG1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2S1NGlEPTB;MUCuNVc{OyEQvF2=MX7TRW5ITVJ?
DSH1NH[yb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoeyTWM2OD1zMD64PFc6KM7:TR?=NEWydXZUSU6JRWK=
SW13NUnqUWpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTFzLkmzNVkh|ryPNHrScnRUSU6JRWK=
MDA-MB-453MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoKyTWM2OD1zMj6xOlA{KM7:TR?=MoDwV2FPT0WU
647-VMoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;aSlhKUUN3ME2xNk4{PTh{IN88US=>MkW5V2FPT0WU
NCI-H2342MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlGyTWM2OD1zMj6zPVk2KM7:TR?=NYTFR41uW0GQR1XS
LB2241-RCCNFnhe|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fpN2lEPTB;MUKuOVc4QSEQvF2=NI\4NlBUSU6JRWK=
UACC-257MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPNTWM2OD1zMz60OFU{KM7:TR?=NGnGU2hUSU6JRWK=
NCI-H661MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTF|Lk[0OFkh|ryPMoXYV2FPT0WU
FADUMmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17iWmlEPTB;MUOuOlk6OiEQvF2=NHfrWlZUSU6JRWK=
A2780MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\aNXdKSzVyPUGzMlgxPDFizszNMlPxV2FPT0WU
NCI-H1793NFuxWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXqxNJc6UUN3ME2xOE41ODh3IN88US=>M1LKb3NCVkeHUh?=
TE-8MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTF3LkO0OlUh|ryPNFLacI5USU6JRWK=
HGC-27M1u3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTF4LkG2OFQh|ryPM4PWd3NCVkeHUh?=
MMAC-SFM{X5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TJZWlEPTB;MUeuN|czPyEQvF2=MYrTRW5ITVJ?
Calu-6MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfJTWM2OD1zOD6xOVE{KM7:TR?=NVfrSItZW0GQR1XS
HUTU-80NX7xWFYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nNd2lEPTB;MUiuN|k2QSEQvF2=MV3TRW5ITVJ?
SASNH7rSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3f0S2lEPTB;MUiuOlQ2PSEQvF2=M3zGSHNCVkeHUh?=
IST-MES1NVH0eIxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTF6Lk[1NFgh|ryPNVHsbpN3W0GQR1XS
C3AM{f0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTF6Lke5NVkh|ryPMnOwV2FPT0WU
ES3MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIq4[lhKSzVyPUG4Mlg{PjRizszNMYDTRW5ITVJ?
HSC-2NIfpRYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3GwZ2lEPTB;MUmuOlU1OSEQvF2=MnjBV2FPT0WU
T47DMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTJyLkG0PFUh|ryPMXTTRW5ITVJ?
EW-7NFTQdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTJyLki1PFgh|ryPM33kPXNCVkeHUh?=
LN-405NXXxRmZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17tUGlEPTB;MkCuPFk3PSEQvF2=MlvIV2FPT0WU
U031Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTJzLkS4NFIh|ryPMYnTRW5ITVJ?
A549NFrHeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTBTWM2OD1{MT64OFkyKM7:TR?=NFjkT5JUSU6JRWK=
RMG-IM{m0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTJ{LkK2Olgh|ryPMWPTRW5ITVJ?
BT-474NIP6TIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7xTWM2OD1{Mj62OVUyKM7:TR?=MVjTRW5ITVJ?
NB69MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;UZWhjUUN3ME2yN{4yPTJizszNMnnaV2FPT0WU
NB7NUjFSHRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTJ2LkG4PEDPxE1?MUXTRW5ITVJ?
HCC1569NHHVdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTvTWM2OD1{ND62NVI2KM7:TR?=Moq3V2FPT0WU
MEL-JUSOMkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37h[WlEPTB;MkSuOlkxQCEQvF2=NWDGenJ7W0GQR1XS
MDA-MB-175-VIIMkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTJ3LkK1NVch|ryPNF3ubXdUSU6JRWK=
HCC1419NWj0VZdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TJ[GlEPTB;MkWuOlAxOyEQvF2=NIHFdZdUSU6JRWK=
Ca9-22MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYGwPYFxUUN3ME2yOU43PDN{IN88US=>MYrTRW5ITVJ?
KGNMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIft[mRKSzVyPUK1Mlc2PDdizszNNVzwUZFDW0GQR1XS
LB373-MEL-DM1LjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\RTWM2OD1{Nj6xPVM5KM7:TR?=MVzTRW5ITVJ?
NCI-H1755NWjOUXR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\vZZdLUUN3ME2yOk45QDRzIN88US=>MUnTRW5ITVJ?
D-423MGNUDUPFVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTJ5LkC3NVUh|ryPMlLrV2FPT0WU
DK-MGNHHQVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTJ6Lke4OFYh|ryPM{Hke3NCVkeHUh?=
NCI-H1623MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTJ6LkizOFIh|ryPM2f6THNCVkeHUh?=
KU-19-19NEDWVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPjU|M5UUN3ME2yPE46QTVizszNMUDTRW5ITVJ?
C-33-AMojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFS4TFZKSzVyPUK5MlIyQThizszNMnTiV2FPT0WU
SCC-4NVnP[IFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3YTWM2OD1|MD6zN|U1KM7:TR?=NUnMVoZPW0GQR1XS
MG-63M1XJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDET|BqUUN3ME2zNE42QTl2IN88US=>M{XwdXNCVkeHUh?=
LNCaP-Clone-FGCNXvGeHIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPid2tpUUN3ME2zNU41QTJzIN88US=>NEW4bGFUSU6JRWK=
CAPAN-1NH\udWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXKWIpGUUN3ME2zNU42Ojh4IN88US=>NETDe5lUSU6JRWK=
GI-ME-NM{WzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3MXpRyUUN3ME2zNU42OzV|IN88US=>MYLTRW5ITVJ?
RERF-LC-MSMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmGwTWM2OD1|Mj62O|Q4KM7:TR?=MX7TRW5ITVJ?
KLEM13ySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jDe2lEPTB;M{OuOFM{PCEQvF2=MVvTRW5ITVJ?
KNS-81-FDNXrqcnhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTN|LkWwNFgh|ryPNIm5c5hUSU6JRWK=
DOKNFvHWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTN2Lk[2NVIh|ryPNXPsPWhPW0GQR1XS
ACHNNHLsS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2T4fGlEPTB;M{WuNVU5QCEQvF2=M4S0[nNCVkeHUh?=
KYSE-520NEHUeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLyTWM2OD1|NT6yN|YyKM7:TR?=MXvTRW5ITVJ?
SBC-5NX3rWGtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml:wTWM2OD1|NT61NVE3KM7:TR?=NFz2PHdUSU6JRWK=
NCI-H28NYXCcIloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTN3Lk[2PVUh|ryPMlrjV2FPT0WU
ES7NXPKVXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\RdmlEPTB;M{[uNlI1QSEQvF2=MnnrV2FPT0WU
A172M2TNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPZTWM2OD1|Nj60NVg4KM7:TR?=M4fxbHNCVkeHUh?=
UM-UC-3MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTN5Lki3OFYh|ryPMXnTRW5ITVJ?
LXF-289NVjZZXZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fpXmlEPTB;M{iuNFA1PyEQvF2=NFSyTWFUSU6JRWK=
KP-4MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTkV2R1UUN3ME2zPE41PzN7IN88US=>NGX2bmNUSU6JRWK=
TE-1M3ezOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfS[ZFKSzVyPUO5MlY2QDlizszNMVPTRW5ITVJ?
G-402NXnU[pFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo[0TWM2OD12MD6wOlEh|ryPMVLTRW5ITVJ?
786-0M{THeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHzWFRsUUN3ME20NE46ODl4IN88US=>M{npT3NCVkeHUh?=
K5NH;aNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXqboVKSzVyPUSxMlM3QDZizszNMWrTRW5ITVJ?
SK-N-DZM1nwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrzTWM2OD12MT6zPFI{KM7:TR?=MoXTV2FPT0WU
OVCAR-4NVfVZ5dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\p[oxKSzVyPUSxMlc2PjhizszNM2\YUHNCVkeHUh?=
T84M2XDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PwdmlEPTB;NEKuNVI3OyEQvF2=MVPTRW5ITVJ?
GCIYM{P5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jSVmlEPTB;NEOuNFgxOyEQvF2=M2XMXnNCVkeHUh?=
BB49-HNCMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLLSnZKSzVyPUSzMlM{PDhizszNNH;uS5hUSU6JRWK=
SNU-C2BNX[0[ZpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnnUY1GUUN3ME20N{43PDN4IN88US=>NX\yVW52W0GQR1XS
TE-6NXz6W4huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2exUWlEPTB;NEOuPFg6PCEQvF2=MVrTRW5ITVJ?
23132-87MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\t[plKUUN3ME20OE4zQTd6IN88US=>NV[zZmdpW0GQR1XS
DMS-53NFniUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTNTWM2OD12ND6zN|g1KM7:TR?=NUXXU|hEW0GQR1XS
ONS-76Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLVbW14UUN3ME20OE44PjZzIN88US=>MnnIV2FPT0WU
DMS-273M3fv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnznTWM2OD12ND65OFMh|ryPNV22NmZDW0GQR1XS
COLO-824NUTtRo1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTD[FRFUUN3ME20OU45Pzd3IN88US=>NHPycGtUSU6JRWK=
DMS-114MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{f4WmlEPTB;NEWuPFkzPyEQvF2=MmPjV2FPT0WU
YKG-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnxOpZQUUN3ME20Ok4xOzV3IN88US=>MVvTRW5ITVJ?
RH-18Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIf6bY5KSzVyPUS2MlM4OzNizszNNEHkfW5USU6JRWK=
NCI-H1355M1ztT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfYc|JKSzVyPUS2MlYyQCEQvF2=NUnzSohQW0GQR1XS
NCI-H2170NH;JdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zTZ2lEPTB;NEeuO|U5PCEQvF2=NH34N2FUSU6JRWK=
OC-314NHv2[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnriTWM2OD12Nz64OFc5KM7:TR?=M3ftW3NCVkeHUh?=
NCI-H2030NVX2cnp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13sTmlEPTB;NEeuPFkxPiEQvF2=NGnOSJNUSU6JRWK=
22RV1MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrzfYtKSzVyPUS3MlkxOTVizszNNX;nWWdvW0GQR1XS
G-401MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PEOGlEPTB;NEiuOFQyPSEQvF2=M3XtXHNCVkeHUh?=
YAPCNWribXo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfCZnhKSzVyPUS5MlgxPzNizszNMmnDV2FPT0WU
SW1573MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XPWWlEPTB;NUCuNlQ{PSEQvF2=MofsV2FPT0WU
COLO-792MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYH5dmQ5UUN3ME21NE43OjN5IN88US=>M3;jT3NCVkeHUh?=
KNS-62M3;Ne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTVyLke1NFgh|ryPMVrTRW5ITVJ?
NB5NHiy[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTVzLkS1NFkh|ryPMYHTRW5ITVJ?
CP66-MELM4KyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrNNYM2UUN3ME21NU43PDB6IN88US=>MmjXV2FPT0WU
CaR-1M3:3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTV{LkC2NFYh|ryPMnf1V2FPT0WU
CAL-54MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTV{LkGxNFIh|ryPNFmxeVFUSU6JRWK=
8305CMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETIbotKSzVyPUWyMlMyPSEQvF2=MnjDV2FPT0WU
Calu-3M3HNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFT6RnNKSzVyPUWyMlM4OzNizszNNITKWplUSU6JRWK=
AU565NYi1NYljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zrRWlEPTB;NUKuOVUxQSEQvF2=M1izenNCVkeHUh?=
CW-2NGDKc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml70TWM2OD13Mj64OlU1KM7:TR?=NUWydJdjW0GQR1XS
BENMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfBTWM2OD13Mz63PFYzKM7:TR?=M4XVTnNCVkeHUh?=
NCI-H1975MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLNTWM2OD13Mz64PVY3KM7:TR?=NXjDPFVOW0GQR1XS
HCT-116M{HtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfOTWM2OD13ND6wN|I4KM7:TR?=M3TUPHNCVkeHUh?=
SH-4NVfBTml1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\k[Y5DUUN3ME21OE4yOzhizszNMUnTRW5ITVJ?
NCI-H1693M3ix[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVH6UplEUUN3ME21OE4zOTB|IN88US=>M1T6ZXNCVkeHUh?=
BPH-1M122[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDOfnRKSzVyPUW1MlI5QTJizszNMV;TRW5ITVJ?
CAMA-1NFH1RVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn3kTWM2OD13NT64NVE3KM7:TR?=MXfTRW5ITVJ?
A388MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\yTWM2OD13Nj6wPVg2KM7:TR?=MYPTRW5ITVJ?
C2BBe1NHT2[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkGwTWM2OD13Nj6yOlM1KM7:TR?=NX35TIZKW0GQR1XS
GAMGMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fiO2lEPTB;NU[uOVk2PSEQvF2=Mn62V2FPT0WU
MKN28MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTV4LkiwNVMh|ryPNIm1enJUSU6JRWK=
VA-ES-BJNHTZWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUG4c2ZZUUN3ME21Ok45PzR3IN88US=>MmK2V2FPT0WU
HuCCT1M3u2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTV5LkC0PVIh|ryPNV\CUppEW0GQR1XS
BFTC-905MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYn6SY1oUUN3ME21O{4zQDl6IN88US=>M4nGTHNCVkeHUh?=
LS-123NWDydYVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnOyTWM2OD13Nz61OlY5KM7:TR?=MWHTRW5ITVJ?
LB996-RCCNULQXYFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTV6LkCyPFch|ryPM4mweHNCVkeHUh?=
NCI-H1048M{iyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfEPFF2UUN3ME21PE4zOTh6IN88US=>MXjTRW5ITVJ?
COR-L105NH\hT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;XTWM2OD13OD63N|M4KM7:TR?=NVu4VnJzW0GQR1XS
OVCAR-8NHvmN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTV7LkG3NVYh|ryPM1;sSnNCVkeHUh?=
SK-N-FIM4LmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDMdHRvUUN3ME21PU4{OjB5IN88US=>MUnTRW5ITVJ?
MES-SAM3fScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3qwUWlEPTB;NUmuOFUxQSEQvF2=M1PwZXNCVkeHUh?=
SCC-9NFzNPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWKzPGNbUUN3ME21PU41PzV|IN88US=>M1X3ZnNCVkeHUh?=
EFO-27Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTrTWM2OD13OT65OFMh|ryPNFrIWldUSU6JRWK=
GT3TKBNH6xW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zxe2lEPTB;NkCuOlA1QCEQvF2=NVPX[VNGW0GQR1XS
HCC38M3zXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LTPGlEPTB;NkGuOFM4QSEQvF2=M2raU3NCVkeHUh?=
MLMAM3LxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3e0NWlEPTB;NkGuOlE3OyEQvF2=NIOx[oNUSU6JRWK=
D-566MGM2Hhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTZ|LkWyNlQh|ryPMUjTRW5ITVJ?
SF295MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PjNGlEPTB;NkOuOlY2PSEQvF2=NFPve49USU6JRWK=
ES4M1zmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjHWWNKSzVyPU[0MlQ4OTlizszNNV;MRplkW0GQR1XS
CAKI-1MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHm3b5FKSzVyPU[0MlU4OjFizszNNIH2cIJUSU6JRWK=
OAW-28MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljuTWM2OD14ND65OlQ4KM7:TR?=M2G1OHNCVkeHUh?=
NCI-H460NHPaSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHkTWM2OD14NT6wPFk4KM7:TR?=NFzwdFJUSU6JRWK=
JARNIfiWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTZ3LkW1NVYh|ryPM2mzenNCVkeHUh?=
SNU-449NHjOd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPGTWM2OD14NT63OlE3KM7:TR?=NGri[5dUSU6JRWK=
D-392MGNGrje2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTZ3Lkm0N|Qh|ryPM3LKZ3NCVkeHUh?=
EW-22MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7KTWM2OD14Nj6zPVUh|ryPNHPweoRUSU6JRWK=
GCTNHvISW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHLTWM2OD14Nz6wOFQ{KM7:TR?=MVLTRW5ITVJ?
NOS-1MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVqwSY9TUUN3ME22O{43QDZ5IN88US=>MX3TRW5ITVJ?
RH-1NV7qPYV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7zTWM2OD14OD61OVU6KM7:TR?=NXW1T3RWW0GQR1XS
HuH-7MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7xXIxyUUN3ME22PU4yODB{IN88US=>MYLTRW5ITVJ?
NUGC-3NEjHW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\ZdWlEPTB;N{CuPVY1PCEQvF2=NXrKd5p4W0GQR1XS
IST-SL1NYDTc5hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTdzLkKzNlQh|ryPMXHTRW5ITVJ?
SHP-77MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3pTWM2OD15Mj6xNVkh|ryPM2nxfXNCVkeHUh?=
SW1116M1LmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTd{LkG0NFch|ryPNYTiXJFGW0GQR1XS
LK-2NVLi[IRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfWZng2UUN3ME23Nk45PjF{IN88US=>MkPmV2FPT0WU
U-2-OSNX\RUpppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnoUGxKUUN3ME23N{4yQDJ6IN88US=>NWS0[2N4W0GQR1XS
KYSE-150M4D6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTd|Lk[xNVgh|ryPMmDIV2FPT0WU
U251MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXHRYhvUUN3ME23N{45OTZ6IN88US=>NI\5RWdUSU6JRWK=
HT-1080MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17LdGlEPTB;N{SuNlU4PCEQvF2=NGT5cG9USU6JRWK=
NCI-H1437MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTd2Lk[zNlYh|ryPNUXBcGdtW0GQR1XS
HPAF-IIMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLrTWM2OD15ND62OFE2KM7:TR?=MnvrV2FPT0WU
BeckerNUPLeXVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\JO2lEPTB;N{WuNVExPSEQvF2=NI\n[YxUSU6JRWK=
PANC-10-05MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrneGNKSzVyPUe1MlI5PjVizszNMYDTRW5ITVJ?
TYK-nuNIrkTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIGyPFBKSzVyPUe1MlMyODJizszNM4j2dHNCVkeHUh?=
SKG-IIIaMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTd3LkOzOFEh|ryPNWD3fHZOW0GQR1XS
NCI-H1993MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH62PIhKSzVyPUe1Mlc{QTdizszNNYixVYt{W0GQR1XS
S-117MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDpUIdKSzVyPUe1Mlc2PSEQvF2=M1W2TXNCVkeHUh?=
HuO9MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vUN2lEPTB;N{[uNFA1QCEQvF2=MXPTRW5ITVJ?
CAL-51M4rLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfVTWM2OD15Nj6xNFA3KM7:TR?=MknhV2FPT0WU
BT-20MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\5TWM2OD15Nj6yNVY5KM7:TR?=M3L4WXNCVkeHUh?=
LB831-BLCM4PKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTd4LkOyNVch|ryPMY\TRW5ITVJ?
LB1047-RCCNEjEdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLCN5NCUUN3ME23Ok44PjF7IN88US=>M1zpenNCVkeHUh?=
ES8MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfyTWM2OD15OD6wNFc{KM7:TR?=MmXsV2FPT0WU
UMC-11NVTKc|VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWCycYpWUUN3ME23PE4xQDh2IN88US=>MorNV2FPT0WU
NCI-H226Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofCTWM2OD15OD6xN|E2KM7:TR?=MnHDV2FPT0WU
IGROV-1Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV72SGxXUUN3ME23PE42PTVizszNNVXES2Y6W0GQR1XS
BHYMoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7ZSHlqUUN3ME23PU42QTZizszNMVvTRW5ITVJ?
MKN45M2C3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlu0TWM2OD16MD6zNVc1KM7:TR?=M{DybHNCVkeHUh?=
IA-LMNUDxUY5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDK[2JKSzVyPUiwMlM2OTFizszNM1fqUHNCVkeHUh?=
WM-115MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXL2XZN1UUN3ME24NU41OTF2IN88US=>M1TqUHNCVkeHUh?=
VMRC-RCZM2S3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTGTWM2OD16MT60OFI2KM7:TR?=MmHvV2FPT0WU
NCI-H2291M1nxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRThzLk[4OFIh|ryPM1[zTnNCVkeHUh?=
MCF7NIPQU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{S3RWlEPTB;OEOuNlg6PyEQvF2=MVjTRW5ITVJ?
639-VM4GwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEf1ZnRKSzVyPUi0MlYyOjlizszNMXzTRW5ITVJ?
RT4M1v5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NET5[oxKSzVyPUi1MlI1ODNizszNMmfDV2FPT0WU
NCI-H2405M3nPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlv3TWM2OD16NT6yPVk4KM7:TR?=Ml\vV2FPT0WU
CAL-33M17SbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFX6WVlKSzVyPUi1MlY{OTVizszNNITVS3dUSU6JRWK=
BT-549NXr6R4M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HXc2lEPTB;OEWuPVM5OiEQvF2=NGjnbIlUSU6JRWK=
HT-1197MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHGV3hKSzVyPUi4MlExPzdizszNM{PK[HNCVkeHUh?=
G-361NEL2NmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4T0S2lEPTB;OEiuNVQ4PCEQvF2=NIXQZmlUSU6JRWK=
LS-411NMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnruTWM2OD16OT6zN|g5KM7:TR?=NVr4boF7W0GQR1XS
HT-144M4j6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnaUYpKSzVyPUi5MlU6QTJizszNM2jyXnNCVkeHUh?=
DJM-1NEPIRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnxUJREUUN3ME24PU45QDR3IN88US=>M1;xbHNCVkeHUh?=
CAL-12TNYHWOXJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLI[ZVVUUN3ME25NE44QDl3IN88US=>MWHTRW5ITVJ?
MKN7MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTlzLkO1OVEh|ryPM3;MfXNCVkeHUh?=
HuP-T3NV7iTm1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTl4LkGwNFQh|ryPMn72V2FPT0WU
SK-MG-1M1LHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXDUHhjUUN3ME25Ok4yOzR6IN88US=>MXfTRW5ITVJ?
NCI-H2347M2X3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fXV2lEPTB;OUiuNVA1OiEQvF2=MX3TRW5ITVJ?
SW872M{LCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTFyMD60OVYh|ryPMXXTRW5ITVJ?
COLO-829M1njfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DXNGlEPTB;MUCwMlU2OyEQvF2=MmHvV2FPT0WU
MC-IXCNHTHWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH:1VJFKSzVyPUGwNE43OTVizszNMWfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Protein kinase activity assays For selectivity IC50 assays, purified active GST–S6K1, GST–S6K2, His–MSK1 (residues 2–802), His–RSK1 (residues 1–735) and His–RSK2 (residues 2–740) (0.5 units/mL) are assayed for 30 min at 30 °C in a 50 μL assay mixture in buffer A containing either 30 μM Crosstide (GRPRTSSFAEG, for S6K1, S6K2 and MSK1) or 30 μM Long S6 (KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK, for RSK1 and RSK2), 10 mM magnesium acetate and 100 μM [γ- 32P]ATP. Reactions are terminated and the incorporation of [γ-32P]phosphate into the peptide substrate is determined by applying the reaction mixture on to P81 phosphocellulose paper and scintillation counting after washing the papers in phosphoric acid. One unit of activity is defined as that which catalysed the incorporation of 1 nmol of [32P]phosphate into the substrate. To determine the Ki for PF-4708671, full-length recombinant S6K1 is added to a final concentration of 5 nM to Omnia assay buffer containing various concentrations of compound. The reaction is run for 60 min at 30 °C in a 50 μL assay volume. The fluorescence of the peptide is monitored at an excitation wavelength of 360 nm and an emission wavelength of 485 nm. The rate of the reaction at each compound concentration is normalized to the DMSO control rate, and this normalized rate against concentration is fitted to the Morrison tight-binding equation for a competitive inhibitor to provide the true Ki. In order to assay S6K activity in HEK-293 cell lysates, cells are lysed in Tris lysis buffer. Lysate (0.5 mg) is incubated with 5 μg of S6K antibody conjugated to Protein G–Sepharose for 1 h at 4 °C on a vibrating platform. Immunoprecipitates are washed twice with lysis buffer and twice with buffer A, and kinase activity is assayed exactly as described above using the Crosstide peptide.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Chemical Information

Download PF-4708671 SDF
Molecular Weight (MW) 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 1H-Benzimidazole, 2-[[4-(5-ethyl-4-pyrimidinyl)-1-piperazinyl]methyl]-6-(trifluoromethyl)-

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related S6 Kinase Products

  • LY2584702

    LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.

  • LY2584702 Tosylate

    LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • BI-D1870

    BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • MK-2206 2HCl

    MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

    Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.

  • CHIR-99021 (CT99021) HCl

    CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.

  • LY294002

    LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

Recently Viewed Items

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us